× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy



meta|IO

Evidence base on efficacy and safety of
Immuno-Oncology drugs

Global living systematic review and meta-analysis of RCTs

Pathology  

Latest studies

JAVELIN Gastric 100 (PDL1>1%), 2020

gastric or gastroesophageal junction cancer (GC)

avelumab alone

CheckMate 274 (PDL1>1%), 2017

urothelial cancer (UC) - bladder cancer (BC)

nivolumab alone

JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021

ovarian cancer (OC)

avelumab plus pegylated liposomal doxorubicin

EMPOWER lung1 (PDL1>50%), 2021

lung cancer : non small cell (NSCLC)

cemiplimab

287
treatments 		  201
studies 		  805
references
This project is supported by H2020 Qualitop, an EU-funded project, Hospices Civils de Lyon and CNRS UMR5558 LBBE.
     

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons